The P/E ratio for Acadia Pharmaceuticals stock stands at 16.03 as of Jun 27, 2025. The calculation is based on the latest EPS of $1.38 and the stock price of $22.12 per share. A decrease of 53% has been observed in the PE ratio compared to its average of 33.9 of the past four quarters.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 13.39 | N/A | $18.35 | $1.37 |
2023 | N/A | N/A | $31.31 | -$0.37 |
2022 | N/A | N/A | $15.92 | -$1.34 |
2021 | N/A | N/A | $23.34 | -$1.05 |
2020 | N/A | N/A | $53.46 | -$1.79 |
2019 | N/A | N/A | $42.78 | -$1.6 |
2018 | N/A | N/A | $16.17 | -$1.94 |
2017 | N/A | N/A | $30.11 | -$2.36 |
2016 | N/A | N/A | $28.84 | -$2.34 |
2015 | N/A | N/A | $35.65 | -$1.63 |
2014 | N/A | N/A | $31.75 | -$0.95 |
2013 | N/A | N/A | $24.99 | -$0.44 |
2012 | N/A | N/A | $4.65 | -$0.38 |
2011 | N/A | N/A | $1.08 | -$0.44 |
2010 | 3.08 | N/A | $1.2 | $0.39 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | 12.04 | -10.08% | $16.61 | $1.38 |
Dec 2024 | 13.39 | -32.1% | $18.35 | $1.37 |
Sep 2024 | 19.72 | -78.16% | $15.38 | $0.78 |
Jun 2024 | 90.28 | N/A | $16.25 | $0.18 |
Mar 2024 | N/A | N/A | $18.49 | -$0.01 |
Dec 2023 | N/A | N/A | $31.31 | -$0.37 |
Sep 2023 | N/A | N/A | $20.84 | -$0.92 |
Jun 2023 | N/A | N/A | $23.95 | -$0.69 |
Mar 2023 | N/A | N/A | $18.82 | -$0.91 |
Dec 2022 | N/A | N/A | $15.92 | -$1.34 |
Sep 2022 | N/A | N/A | $16.36 | -$1.35 |
Jun 2022 | N/A | N/A | $14.09 | -$1.27 |
Mar 2022 | N/A | N/A | $24.22 | -$1.33 |
Dec 2021 | N/A | N/A | $23.34 | -$1.05 |
Sep 2021 | N/A | N/A | $16.61 | -$1.2 |
When compared to its peer stocks LLY and JNJ, ACAD's PE ratio is lower. Acadia Pharmaceuticals is currently trading at a lower PE ratio (16.03) than its peers average of 28.59.
Stock name | PE ratio | Market cap |
---|---|---|
ACAD Acadia Pharmaceuticals Inc | 16.03 | $3.7B |
JNJ Johnson & Johnson | 16.82 | $366.71B |
BMY Bristol Myers Squibb Co | 17.29 | $94.33B |
PFE Pfizer Inc | 17.4 | $137.53B |
LLY ELI LILLY & Co | 62.84 | $734.92B |
VNDA Vanda Pharmaceuticals Inc | N/A | $281.71M |
The price to earnings ratio for ACAD stock as of Jun 27, 2025, stands at 16.03.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Jun 27, 2025), Acadia Pharmaceuticals's share price is $22.12. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $1.38. Therefore, Acadia Pharmaceuticals's price to earnings ratio for today is 16.03. PE RATIO(16.03) = STOCK PRICE($22.12) / TTM EPS($1.38)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.